Oncology Frontier:What are the new drugs that have become available for triple-negative breast cancer?

　　《肿瘤瞭望》：目前有哪些有效的三阴性乳腺癌新药？

　　Dr Telli: One of the areas that is getting a lot of attention and there is a lot of enthusiasm around， are the new drugs targeting the body’s immune system to treat cancer. We have seen data in many other types of cancer (melanoma， lung and kidney cancer) looking at these new antibody-based treatments that target PD1 or PD-L1. In December， at the San Antonio Breast Cancer Symposium， we saw that in two small studies， these drugs showed activity in patients with pretreated advanced triple-negative breast cancer. I think this has demonstrated proof of concept and there is a lot of enthusiasm to expand research with these and related drugs for patients with triple-negative breast cancer. In the years ahead， we are going to see a lot more action in this field. Like anything， not all patients are going to benefit from this approach， but certainly we do now have evidence that some patients respond well to these immunotherapies.

　　Telli博士：其中一类新药是免疫治疗药物，免疫治疗是目前癌症研究热点，黑色素瘤、肺癌和肾癌免疫治疗（比如抗PD-1或PD-L1抗体）已有相当多的研究数据。在2014年12月的圣安东尼奥乳腺癌研讨会上，两个小规模研究显示，免疫治疗药物复治三阴性晚期乳腺癌显示出活性，为三阴性乳腺癌免疫疗法提供了证据（Proof of Concept），目前研究者们强烈希望扩大这类免疫治疗药物（及相关药物）治疗三阴性乳腺癌的研究。以后这类研究会有很多。当然，并非所有患者都能从中获益，但目前的证据表明，一部分患者免疫治疗的反应良好。